Martinsried/Munich, September 19, 2012. Medigene AG (MDG, Frankfurt, Prime Standard) announces the appointment of Peter Llewellyn-Davies as member of the company's Executive Management Board with effect from 1 October 2012
To date Chief Financial Officer of Wilex AG, Munich, the Briton Peter Llewellyn-Davies was responsible for a broad range of functions including accounting, controlling, finance, legal, human resources and investor relations. He was a member of Wilex's Executive Management Board from 2006 until the end of August 2012. Over the last six years, he has been instrumental in the initial public offering, key strategic transactions and acquisitions as well as their integration, and a range of capital measures. Prior to this, he was Managing Director of Müller Dairy (UK) and Executive Finance Director at Süd-Chemie AG, where he oversaw the international expansion of the Munich-based company.
At Medigene AG, Peter Llewellyn-Davies succeeds Arnd Christ, who is leaving the company at his own request after two-and-a-half successful years as CFO in order to pursue a new professional challenge.
Chairman of the Supervisory Board of Medigene AG, Dr. Ernst-Ludwig Winnacker, commented: "On behalf of the Supervisory Board, I would like to thank Mr Christ for the excellent work he has carried out over the last two-and-a-half years since he became CFO of Medigene AG and wish him all the best in his future endeavours. With Mr Llewellyn-Davies we have been able to attract an international finance expert with management experience in the biotechnology sector to our Board. In the past, he has successfully demonstrated his expertise in corporate finance, M&A and investor relations. I am certain that the activities of the Executive Board will benefit enormously from his knowledge and that he will generate valuable new impetus."
Dr. Frank Mathias, Chief Executive Officer of Medigene AG remarked: "I am pleased that we have now been able to successfully conclude our discussions and to have Peter Llewellyn-Davies on board. He perfectly complements the Executive Board and joins us at a decisive moment in Medigene's development: the recently concluded focusing of the product portfolio and organisation has securely placed Medigene in a strong position for a new period of growth. For this strategy, Peter's acumen and track record acquired on the international capital markets through many transactions is a highly appreciated addition and a perfect fit."
"The new role at Medigene offers me the kind of exciting entrepreneurial challenge I have been looking for. I am really looking forward to working with Frank Mathias and his dedicated team," says Peter Llewellyn-Davies. "Following the successful reorientation of the company, the objective is to drive the growth strategy of Medigene AG, achieve the full potential available and help to increase awareness of Medigene on the domestic and international capital markets as a listed company."
Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials and is developing an innovative vaccine technology.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
- ends -
Contact Medigene AG
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.